Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3

Blood

Volumn 118, Issue 8, 2011, Pages 2239-2242

  Walz, Christoph ^a   Erben, Philipp ^b   Ritter, Michael ^c   Bloor, Adrian ^d   Metzgeroth, Georgia ^b   Telford, Nick ^d   Haferlach, Claudia ^e   Haferlach, Torsten ^e   Gesk, Stefan ^f   Score, Joannah ^g,h   Hofmann, Wolf Karsten ^b   Hochhaus, Andreas ⁱ   Cross, Nicholas C P ^g,h   Reiter, Andreas ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KLINIKUM IBBENBÜREN   (Germany)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

^g WESSEX REGIONAL GENETICS LABORATORY   (United Kingdom)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYSTEINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; HYBRID PROTEIN; PREDNISONE; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR ETV6; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASE REPORT; CAUSE OF DEATH; CELL NUCLEUS; CHROMOSOME TRANSLOCATION 12; CHROMOSOME TRANSLOCATION 13; CHROMOSOME TRANSLOCATION 9; CYTOGENETICS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EOSINOPHILIA; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERPHASE; INTRON; LEUKOCYTOSIS; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOBLASTOMA; MALE; MULTIPLE CYCLE TREATMENT; MYELOID LYMPHOID NEOPLASM WITH EOSINOPHILIA; OFF LABEL DRUG USE; PANCYTOPENIA; PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; REPEAT PROCEDURE; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT DURATION; WHOLE BODY RADIATION;

EID: 80052162708     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343426     Document Type: Article

References (15)

1. Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci. 2004;61(23):2912-2923. (Pubitemid 40104589)
2. Reiter A, Walz C, Cross NCP. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets. 2007;8(2):205-216.
3. Metzgeroth G, Walz C, Erben P, et al. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol. 2008;143(5):707-715.
4. Macdonald D, Reiter A, Cross NCP. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107(2):101-107. (Pubitemid 34264174)
5. Vu HA, Xinh PT, Masuda M, et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia. 2006;20(8):1414-1421. (Pubitemid 44084055)
6. Baldwin BR, Li L, Tse KF, et al. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia. 2007;21(4):764-771. (Pubitemid 46444561)
7. Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol. 2007;35(11): 1723-1727. (Pubitemid 47633767)
8. Chase A, Reiter A, Burci L, et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13; q12). Blood. 1999;93(3):1025-1031. (Pubitemid 29067868)
9. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183-1188. (Pubitemid 46831806)
10. Adelaide J, Perot C, Gelsi-Boyer V, et al. A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma. Leukemia. 2006;20(3):536-537. (Pubitemid 43291763)
11. Zuna J, Zaliova M, Muzikova K, et al. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer. 2010;49(10):873-884.
12. Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol. 2007;138(1):77-81. (Pubitemid 46889792)
13. Metzelder S, Wang Y, Wollmer E, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113(26):6567-6571.
14. Reiter A, Sohal J, Kulkarni S, et al. Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood. 1998;92(5):1735-1742. (Pubitemid 28406879)
15. Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001; 98(13):3778-3783.